of carotid artery stenting (CAS) relative to carotid endarterectomy (CEA) among Medicare patients has not been established. We compared effectiveness of CAS versus CEA among Medicare beneficiaries. . Medicare patients were followed up from procedure date until death, stroke/transient ischemic attack, periprocedural myocardial infarction, or a composite end point for these outcomes. We derived high-dimensional propensity scores using registry and Medicare data to control for patient factors and adjusted for provider factors in a Cox regression model comparing CAS with CEA. Among 5254 Society for Vascular Surgery's Vascular Registry (1999 CAS; 3255 CEA) and 4055 Carotid Artery Revascularization and Endarterectomy Registry (2824 CAS; 1231 CEA) Medicare patients, CAS patients had a higher comorbidity burden and were more likely to be at high surgical risk (Society for Vascular Surgery's Vascular Registry: 96.7% versus 44.5%; Carotid Artery Revascularization and Endarterectomy Registry: 71.3% versus 44.7%). Unadjusted outcome risks were higher for CAS. Mortality risks remained elevated for CAS after adjusting for patient-level factors (hazard ratio, 1.24; 95% confidence interval, 1.06-1.46). After further adjustment for provider factors, differences between CAS and CEA were attenuated or no longer present (hazard ratio for mortality, 1.13; 95% confidence interval, 0.94-1.37). Performance was comparable across subgroups defined by sex and degree of carotid stenosis, but there was a nonsignificant trend suggesting a higher risk of adverse outcomes in older (>80) and symptomatic patients undergoing CAS. Conclusions-Outcomes after CAS and CEA among Medicare beneficiaries were comparable after adjusting for both patientand provider-level factors. (Circ Cardiovasc Qual Outcomes. 2016;9:275-285.
S troke is a leading cause of death and of years of life lost worldwide. 1 Annually, >40 000 strokes may be attributable to extracranial internal carotid artery stenosis in the United States. 2 Carotid artery stenting (CAS) has emerged as a less invasive alternative to carotid endarterectomy (CEA) for stroke prevention among patients with severe carotid artery stenosis. After the 2004 publication of the Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial demonstrating CAS noninferiority relative to CEA in high-surgical risk patients, 3 the Centers for Medicare and Medicaid Services issued a National Coverage Determination (NCD) covering May 2016 CAS for high-surgical risk patients. In 2010, the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) showed that CAS was equivalent to CEA in nonhigh-surgical risk patients although, during the periprocedural period, CAS patients had more strokes than CEA patients who had more myocardial infarctions (MIs). 4 Although evidence from trials offer guidance for treating patients with carotid artery stenosis, they do not reflect the diversity of patient risk profiles or operator technical variability in the real world. The objective of this study was to compare outcomes after CAS and CEA among Medicare patients overall and in subgroups defined by demographic and clinical characteristics.
Methods

Data Sources
We conducted a retrospective cohort study using the Society for (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) . SVS-VR, now the Vascular Quality Initiative, has no exclusion criteria and collects data on medical history, preprocedural diagnostics, the procedures, as well as predischarge and some postdischarge outcomes for CAS and CEA. 5 To verify data accuracy and completeness, data are cross matched to voluntary submissions of hospital billing data (B.K. Lal, MD, email, unpublished data, 2013). The CARE registry, now the Peripheral Vascular Intervention Registry, was also a voluntary, hospital-based registry and collected similar data on CAS and CEA. 6 Minimum completeness requirements ranged from 95% to 100% for data elements, and records with questionable or missing data were returned to the site for correction before being aggregated in the final data set. 6 From the Centers for Medicare and Medicaid Services, we obtained Medicare data from January 1, 2000, to December 31, 2009, for inpatient CAS procedures (International Classification of Diseases, Ninth Revision, Clinical Modification codes: 00.61, 00.63, and 00.64) from 2005 to 2009 and CEA procedures (International Classification of Diseases, Ninth Revision, Clinical Modification codes: 38.12) from 2000 to 2008. The denominator file contains information on demographics (including race, categorized as white/not white) and enrollment; institutional file on inpatient and outpatient services covered under Medicare parts A and B; noninstitutional file on claims submitted for physician services covered under part B; and vital status file on date of death. We linked the SVS-VR and CARE registry to Medicare data using an accurate approach (Methods section and Tables I and II in the Data Supplement). 7 Briefly, we linked CAS and CEA procedures to the Medicare institutional file using birth date, sex, facility, and the procedure date. We linked the American Hospital Association's Annual Survey Database to Medicare using Medicare provider identifiers to obtain information on hospital organizational structure and size. We used unique physician identification numbers or national provider identifiers to link the American Medical Association's Physician Masterfile to Medicare data to obtain physician demographic and practice data.
Study Population
Medicare fee-for-service beneficiaries who were at least 66 years of age and enrolled in Medicare for at least one year before undergoing their first CAS/CEA at SVS-VR- (2005) (2006) (2007) (2008) 
Outcomes
Outcomes included death, stroke/transient ischemic attack (TIA), and periprocedural MI. We obtained date of death from the Medicare vital status file. Because of shared symptomatology, subjective nature of the diagnosis, and upcoding possibility, we used registry data to identify strokes occurring during the index hospitalization (SVS-VR: an intraprocedural or postprocedural stroke; CARE: new stroke or TIA not resolved before discharge) and identified subsequent hospitalizations for stroke/ TIA using a validated algorithm (433.x1, 434.x1, 435.x, or 436 in the primary or secondary position; positive predictive value without 435.x: 88.6%). 8 Periprocedural MI was defined as an MI during the index hospitalization as per the registries or a subsequent hospitalization for MI or acute coronary syndrome (International Classification of Diseases, Ninth Revision, Clinical Modification: 410.xx or 411.xx in the primary or secondary position; positive predictive value for 410: 96%; positive predictive value for 411: 86%) 9 within 30 days of the procedure. We combined these outcomes into a composite end point.
We followed patients from the CAS/CEA date until the earliest of the following events: the outcomes, loss of Medicare eligibility, or the end of the study (December 31, 2009).
Study Variables
Information on age, sex, and race were obtained from the Medicare denominator files. We used institutional and noninstitutional claims to estimate the Elixhauser comorbidity score 10 and measures of healthcare use. Registry data were used to define high surgical risk according to the SAPPHIRE criteria ( Table III in Information on physician age, sex, foreign medical graduate (yes/no), years since medical school graduation, type of practice (direct patient care/other), present employment (group practice/not in group practice), and region of practice (Northeast, South, Midwest, and West) was obtained from the American Medical Association's Physician Masterfile. We categorized physician specialty based on the information obtained from Medicare noninstitutional claims reported at the time of the procedure. To calculate physician procedure volume, we identified performing physicians using unique physician identification numbers or national provider identifiers. We converted unique physician identification numbers to national provider identifiers for all but 4% of CAS and 7% of CEA procedures. We selected the most experienced physician when >1 physician was listed (9.0% and 2.2% for SVS-VR and CARE CAS procedures, respectively, and 29.7% and 33.7% for SVS-VR and CARE CEA procedures, respectively). We counted procedures performed on Medicare patients and categorized past-year procedural volume as low (<5 CAS/ CEA), medium (CAS: 5-9; CEA: 5-20), or high (CAS ≥10; CEA: ≥21) as guided by the distribution, our previous work, 12, 13 as well as SAPPHIRE and CREST volume benchmarks. 3, 4 Physician identifiers were missing for 15.7% SVS-VR and 15.8% CARE CAS procedures and 6.0% of SVS-VR and 9.1% of CARE CEA procedures.
From the American Hospital Association's Annual Survey Database, we categorized hospitals in terms of teaching hospital status (yes/no), hospital ownership (government, not-for-profit, and forprofit), and size (<200, 200-399, 400-599, 600-999, and ≥1000 total licensed hospital beds). Hospitals with a stroke center were those certified by the Joint Commission as primary stroke centers. To calculate hospital CAS and CEA volume, we used International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes. Medicare institutional identifiers were missing for 5.5% of SVS-VR and 3.9% of CARE CAS procedures and for <1% of CEA procedures in both registries. We counted procedures performed on Medicare patients and dichotomized past-year hospital volume as high or low (CAS: <40; CEA: <30).
Statistical Analysis
Baseline characteristics of CAS or CEA patients in each registry are reported using percentages for categorical variables and means and SDs and medians and interquartile ranges for continuous variables. We report unadjusted risks and 95% confidence intervals (CIs) for the outcomes derived from Kaplan-Meier estimators. We used multiple imputation for missing registry values using registry and claims data.
To compare CAS with CEA, we used Cox regression and report unadjusted, demographic-adjusted, patient-level-adjusted, and patient-and provider-level-adjusted estimates. The high-dimensional propensity score is an algorithm that empirically selects codes or covariates from data dimensions for inclusion in the propensity score on the basis of their confounding potential. 14 Variables selected by the high dimensional propensity score, which collectively act as proxies of the patient's health status, were added to the pre-specified list of important potential confounders (age, sex, race, health service use variables, Elixhauser comorbidity score, and year of procedure). Data dimensions are collections of codes and variables preceding the procedure date, derived from how databases are inherently organized. In this study, claims data dimensions included inpatient diagnoses, inpatient procedures, outpatient diagnoses, outpatient procedures, noninstitutional (carrier) diagnoses, noninstitutional (carrier) procedures, nursing home diagnoses, and nursing home procedures. The registrybased dimensions consisted of variables on medical history, symptomatic status, diagnostic imaging results, preprocedural medications, and high-surgical risk status. In primary analyses, propensity scores were categorized into quintiles and adjusted in the outcome model. We further adjusted for characteristics of the performing physician (past-year procedure volume, census region of practice, foreign medical graduate) and hospital (past-year procedure volume, teaching status, stroke center, ownership type, size) by including the variables directly in the Cox regression (outcome) model. We included an indicator variable in the model to account for missing provider data. We first derived registry-specific estimates and overall estimates using Cox regression, stratifying on registry. We also compared procedures across subgroups defined by age, sex, symptomatic status, and degree of carotid stenosis. The Sandwich variance estimator was used to adjust for clustering. Analyses were performed using SAS versions 9.2 and 9.3 (SAS Institute, Cary, NC). The study was approved by Brigham and Women's Hospital's and NCDR's institutional review boards.
Results
Characteristics of Study Population
We linked 71% and 69% SVS-VR CAS and CEA procedures to Medicare data. Among the 1999 CAS and 3255 CEA patients treated by 337 physicians across 69 centers in the SVS-VR, the distribution of age (mean, 76), male sex (59% versus 58%), and white race (93% versus 94%) was similar ( Table 1) . Almost all CAS and ≈50% of CEA patients were at high surgical risk; age >80 was the most common high surgical risk criteria met (≈25%). CAS patients were more often symptomatic (47% versus 37%), in a clinical trial (29% versus 0.1%), undergoing the procedure during a nonelective hospitalization (24% versus 13%), and had a heavier comorbidity burden than CEA patients (mean Elixhauser score, 4.9 versus 3.3). Nearly 50% and 75% of CAS and CEA procedures were performed by vascular surgeons, respectively. Mean past-year physician procedural volume was 11 for CAS and 33 for CEA. We linked 63% of CAS and 70% of CEA CARE records to Medicare data. After applying inclusion/exclusion criteria, we had 2824 CAS patients and 1231 CEA patients. The distribution of age, sex, race, trial enrollment, type of hospital admission, and overall comorbidity burden, was similar for SVS-VR and CARE patients but CARE patients were less often symptomatic (39% for CAS and 34% for CEA; Table  2 ). A similar proportion of CEA patients in SVS-VR and CARE were at high surgical risk, but only 71% of CAS CARE patients were at high surgical risk. More than half (56%) of CAS procedures were performed by cardiologists and more than one third (37%) of CEA procedures were performed by vascular surgeons. There were 449 physicians across 138 centers performing the procedures. Compared to SVS-VR, mean past-year physician volume in CARE was higher for CAS (17) but lower for CEA (20) and fewer procedures were performed in teaching hospitals. At 3 years, outcome risks remained higher for CAS, whereas stroke/TIA risk after CEA became more comparable across registries ( Table V in the Data Supplement). Unadjusted Kaplan-Meier cumulative mortality curves for SVS-VR and CARE ( Figure 2 ) suggest higher unadjusted mortality risks for CAS. Increased risk was evident during the periprocedural period and risk remained slightly increased over time for CAS patients. A similar pattern was observed for stroke/ TIA in the SVS-VR, whereas for CARE, the curves seemed to diverge later during the postprocedural period ( Figure  3) . Unadjusted death and stroke/TIA risks at 3 years were higher for CAS than for CEA patients. Stroke/TIA risks were slightly lower for CAS patients in the CARE registry than in SVS-VR. Table 3 shows unadjusted and adjusted estimates comparing CAS relative to CEA over the study period in the combined SVS-VR and CARE registries (Tables VI and Table VII in the Data Supplement, registry-specific results). Unadjusted hazard ratios (HRs) for all outcomes except periprocedural MI favored CEA. Propensity score c-statistics ranged from 0.94 to 0.95. After adjustment for patient-level characteristics, only the HR for mortality remained elevated (HR, 1.24; 95% CI, 1.06-1.46). After adjusting for patient-and provider-level characteristics, CAS was comparable to CEA on all outcomes.
Comparative Effectiveness of CAS Versus CEA
Comparative Effectiveness of CAS Versus CEA by Subgroup
Unadjusted risks of mortality and the composite outcome were higher for CAS than for CEA across all subgroups in both registries ( 
Sensitivity Analyses
We used other adjustment techniques to account for propensity scores in sensitivity analyses: matching and including the propensity score as quintiles in the outcome model after 5% trimming, which produced similar results (Tables VI-VIII in  the Data Supplement) . We used an alternative definition for stroke, one without TIA, which yielded consistent results (Tables VI-VIII in the Data Supplement).
Discussion
Main Findings
Medicare-linked CARE and SVS-VR CAS patients were more likely at high surgical risk with a higher comorbidity burden than CEA patients, likely representing real-world approaches to patient selection and adherence to the indication as per the NCD for CAS. CAS patients tended to have higher unadjusted outcome risks. When accounting for patient-and provider-level factors, CAS and CEA performance was comparable, but estimates for mortality favored CEA when adjusting for patient-level factors only. We found a nonsignificant trend, suggesting that CEA may be associated with a lower risk of adverse outcomes in older and symptomatic patients.
Strengths and Limitations
A major strength of this study comes from linking 2 registries with Medicare data. We accounted for factors such as indication and symptomatic status, maximized confounding control using high-dimensional propensity scores derived using Medicare and registry data, and controlled for provider-level factors. Neither of the registries had enrollment criteria and represent real-world Medicare patients under the NCD treated by the 2 groups of specialists most likely to perform CAS and CEA: cardiologists and vascular surgeons. We also performed multiple sensitivity analyses, and our results were robust. Because the NCD covers CAS for high-surgical risk patients and the registries do not capture all Medicare carotid revascularizations, the main limitation of our study is the lack of power and the ability to stratify estimates across all subgroups of interest (eg, restenosis or contralateral occlusion). Stroke territory was also not considered, and postdischarge definitions of stroke/TIA and MI were claims-based only capturing events resulting in hospitalizations. True incidence might be overestimated by including TIA in the stroke algorithm and acute coronary syndrome in the MI algorithm although misclassification should be nondifferential. Finally, we could not compare carotid revascularizations with medical management.
Comparisons With Other Studies
Populations undergoing CAS and CEA were different; CAS patients were sicker and predominantly at high surgical risk. This is in line with what has been previously reported 5, 15 and is expected under the NCD, which covers CAS for Medicare beneficiaries at high surgical risk. Unadjusted comparisons favored CEA with an increase in risk occurring immediately after the procedure. Increased baseline risk of CAS seems to be driven mainly by high-surgical risk factors as controlling for them had the greatest effect on adjusted estimates. 16 Although patient-level adjustment drove comparative estimates toward the null, accounting for provider-level factors, such as past-year physician and hospital procedural volume, teaching affiliation, stroke center status, and hospital size, tended to drive estimates down further. Previous studies have established an association between physician and hospital volume and periprocedural mortality, 12,13,17 a volume-outcome relationship for CEA, 18, 19 and that provider factors other than volume may affect outcomes. 20 Our finding that controlling for provider-level factors in addition to patient-level factors further drove estimates towards the null suggests that provider characteristics affecting outcomes differed between CAS and CEA and are likely more variable in CAS.
A study including patients with similar age, sex, race, and comorbidity distribution that adjusted for patient-level factors and hospital teaching status found similar comparative estimates for death (HR, 1.32; 95% CI, 1.02-1.71) and stroke (HR, 1.28; 95% CI, 0.90-1.79) without provider-level adjustment. 15 In addition, although the majority of our population was asymptomatic, long-term outcome risks also did not differ between ‡Adjusted for the propensity score. §Adjusted for the propensity score, foreign medical graduate, teaching hospital, stroke center, census region of practice, ownership type (for profit, not for profit, government), size of hospital (<200 licensed beds, 200-399, 400-599, 60-999, and ≥1000), physician procedure volume (low, medium, and high), and hospital procedure volume (low or high). CAS and CEA among symptomatic patients in the International Stenting Study (ICSS), 21 Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S), 22 or Stent-Protected Angioplasty Versus Carotid Endarterectomy (SPACE) trials. 23 The CREST trial 4,24 found a significant interaction between age and treatment efficacy, with greater CAS efficacy among younger patients and greater CEA efficacy among older patients, with a crossover around the age of 70 years. We observed a statistically nonsignificant trend, suggesting that older patients (>80) may derive greater benefits from CEA, which may be explained by increased stroke risk with older age because of increased arterial tortuosity or lesion calcification. 24 Our estimates stratified by symptomatic status were similar to those from the CREST trial (symptomatic HR [95% CI], 1.26 [0.81-1.96]; asymptomatic HR [95% CI], 1.02 [0.55-1.86]). 4, 25 Although the interaction with symptomatic status in the CREST trial and in our study was not statistically significant, the possibility that CEA may be more beneficial among symptomatic patients cannot be ruled out.
Implications for Practice and Future Research
Medicare patients undergoing CAS are predominantly at high surgical risk and have a heavier comorbidity burden than their counterparts undergoing CEA. CAS patients had a higher unadjusted risk of death and stroke over the study period. After adjusting for patient-level factors only, CAS was associated with a slightly higher risk of mortality. Adjustment for both patient-and provider-level factors revealed that CAS and CEA were comparable overall and across most subgroups. CAS seems to be as effective as CEA for the treatment of carotid artery stenosis among Medicare beneficiaries under the NCD, especially when performed by qualified providers, but further research is needed to confirm whether older and symptomatic patients may derive greater benefit from CEA than CAS.
